Stockscreener 앱 받기
7.73
12.16%
-1.07
시장 영업 전:
7.71
-0.02
-0.26%
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
Ocular Therapeutix First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Ocular Therapeutix (OCUL) Maintained as Buy by Needham, Price Ta - GuruFocus
Ocular Therapeutix Advances in Retinal Treatment Trials - TipRanks
Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus
Ocular Therapeutix: Q1 Earnings Snapshot - MySA
Ocular Therapeutix sees cash runway into 2028 - TipRanks
Ocular Therapeutix (OCUL) Stock Drops 13% After Q1 Earnings - Benzinga
Ocular Therapeutix reports Q1 EPS (38c), consensus (28c) - TipRanks
Ocular Therapeutix Inc earnings missed by $0.09, revenue fell short of estimates - Investing.com Nigeria
Ocular Therapeutix Inc (OCUL) Q1 2025 Earnings: EPS of $(0.38) M - GuruFocus
Ocular Therapeutix stock tumbles as Q1 results miss estimates By Investing.com - Investing.com Canada
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Ocular Therapeutix Inc reports results for the quarter ended March 31Earnings Summary - TradingView
OCULAR THERAPEUTIX, INC SEC 10-Q Report - TradingView
OCUL's Financial Position: Cash Reserves Expected to Sustain Until 2028 | OCUL Stock News - GuruFocus
Ocular Therapeutix Inc (OCUL) Q1 2025 Earnings: EPS of $(0.38) Misses Estimate, Revenue Falls Short at $10.7 Million - GuruFocus
Ocular Therapeutix (OCUL) Advances Retinal Therapy Pipeline Amid Revenue Miss | OCUL Stock News - GuruFocus
Ocular Therapeutix Q1 Net Loss Narrows, Revenue Falls - marketscreener.com
Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights | OCUL Stock News - GuruFocus
Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights - The Manila Times
Ocular Therapeutix Reports First Quarter 2025 Results and Business Highlights - TradingView
BRIEF-Ocular Therapeutix Q1 EPS USD -0.38 Vs. IBES Estimate USD -0.29 - TradingView
Ocular Therapeutix Earnings: $349M War Chest Powers AXPAXLI Trials as FDA Backs NPDR Program - Stock Titan
Ocular Therapeutix Inc (OCUL) Q1 2025: Everything You Need To Kn - GuruFocus
Neuropathic Ocular Pain Pipeline 2025: In-depth Clinical - openPR.com
Ocular Therapeutix™ to Participate in Upcoming Investor and Scientific Conferences - GlobeNewswire
Ocular Therapeutix to Present Groundbreaking Retina Treatment Results Across 5 Major Healthcare Events - Stock Titan
Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025 - GlobeNewswire
JPMorgan Chase & Co. Has $1.62 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - Defense World
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Ocular Therapeutix Inc’s Market Journey: Closing Strong at 7.91, Up 3.94 - DWinneX
How To Trade (OCUL) - news.stocktradersdaily.com
Hydrogel-Based Drug Delivery System Market Detailed In New - openPR.com
Investors bid Ocular Therapeutix (NASDAQ:OCUL) up US$202m despite increasing losses YoY, taking three-year CAGR to 24% - simplywall.st
Primary Open Angle Glaucoma Therapeutics Market Size in 7MM - openPR.com
Ocular Therapeutix (NASDAQ:OCUL) Now Covered by William Blair - MarketBeat
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listin - GuruFocus
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Strategic Hire: Ocular Therapeutix Strengthens Leadership with Key Payer Access Executive - Stock Titan
Key Trends Shaping the Future of Ocular Implants Market:Ocular Therapeutix Launches Clinical Trial For Axit... - WhaTech
William Blair Initiates Coverage of Ocular Therapeutix (OCUL) with Outperform Recommendation - MSN
DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
Ocular Hypertension Pipeline Analysis and Clinical Trials - openPR.com
Expert Outlook: Ocular Therapeutix Through The Eyes Of 5 Analysts - Benzinga
William Blair starts Ocular Therapeutix stock with Outperform By Investing.com - Investing.com Canada
This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
William Blair Initiates Ocular Therapeutix With Outperform Rating - marketscreener.com
Buy Recommendation for Ocular Therapeutix: Axpaxli’s Potential to Revolutionize nAMD Treatment - TipRanks
Ocular Therapeutix at Needham Conference: Strategic Moves in Eye Care By Investing.com - Investing.com Canada
Ocular Therapeutix at Needham Conference: Strategic Moves in Eye Care - Investing.com India
How to Take Advantage of moves in (OCUL) - news.stocktradersdaily.com
Top Premarket Decliners - MarketScreener
Ocular Therapeutix™ to Participate in Two Investor Conferences in April - The Manila Times
Exclusive: Ocular Therapeutix Leadership Sets Major Investor Presentations for April - Stock Titan
Why Investors Shouldn't Be Surprised By Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) P/S - simplywall.st
0.39%
3.66%
자본화:
|
볼륨(24시간):